The Leukemia & Lymphoma Society (LLS) is the largest voluntary health organization dedicated to funding research, finding cures and ensuring access to treatments for blood cancer patients. For more than 65 years LLS has invested more than $1B to advance cancer therapies and save lives.

The Therapy Acceleration Program (TAP) is a strategic initiative of LLS to accelerate the development of innovative blood cancer treatments, supportive care, and diagnostics that have the potential to change the standard of care for patients with blood cancer, especially in areas of high unmet medical need.

TAP funding is different from the traditional grant at LLS. The TAP review process is separate from the grant process and each approved project is closely monitored by TAP staff.